CD14 and amyotrophic lateral sclerosis: In addition, several studies focused on immune-modulatory strategies, such as NP001 and the anti-CD14 antibody IC14, aimed at modulating systemic and neuroinflammatory processes implicated in ALS progression (Benatar et al., 2024; Forrest et al., 2024; Gelevski et al., 2023; Meininger et al., 2017; Vucic et al., 2020).